Prespecified After-effects Elicited from Robotic Force Fields

Robots have a promising future in the area of training, particularly in neurorehabilitation. However, the most effective training algorithm has yet to be determined. Here we capitalize what is known about implicit learning in motor adaptation : – Repeated exposure to a force field leads the original movement being recovered. – Subjects do this by canceling the forces of the field. – When the disturbing force field is unexpectedly removed, subjects exhibit after-effects. (Shadmehr & Mussa-Ivaldi, 1994).

[1]  R. Castelluccio [Introduction to neuropsychopharmacology]. , 1961, El Dia medico.

[2]  M. Lorr,et al.  Manual for the Profile of Mood States , 1971 .

[3]  H. Norris The action of sedatives on brain stem oculomotor systems in man. , 1971, Neuropharmacology.

[4]  I. Magnussen,et al.  The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man. , 2009, Acta pharmacologica et toxicologica.

[5]  S. Yen,et al.  A mid-day surge in cortisol levels. , 1979, The Journal of clinical endocrinology and metabolism.

[6]  F. Nielsen‐Kudsk,et al.  Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. , 2009, Acta pharmacologica et toxicologica.

[7]  G. Brandenberger,et al.  Diurnal cortisol peaks and their relationships to meals. , 1982, The Journal of clinical endocrinology and metabolism.

[8]  F. Holsboer The dexamethasone suppression test in depressed patients: clinical and biochemical aspects. , 1983, Journal of steroid biochemistry.

[9]  A. Steiger,et al.  CORTICOTROPIN-RELEASING-FACTOR INDUCED PITUITARY-ADRENAL RESPONSE IN DEPRESSION , 1984, The Lancet.

[10]  W. Vale,et al.  Effect of synthetic ovine corticotropin-releasing factor: Prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol , 1984 .

[11]  S. Lamberts,et al.  Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. , 1984, The Journal of clinical endocrinology and metabolism.

[12]  F. Holsboer,et al.  Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. , 1984, The New England journal of medicine.

[13]  K. Shizume,et al.  EFFECT OF METOCLOPRAMIDE ON PLASMA VASOPRESSIN IN MAN , 1984, Clinical endocrinology.

[14]  W. Vale,et al.  Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. , 1984, The Journal of clinical investigation.

[15]  C. Marchesi,et al.  Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man. , 1986, British journal of clinical pharmacology.

[16]  A. Caiazza,et al.  MUSCARINIC CHOLINERGIC, BUT NOT SEROTONINERGIC MEDIATION OF ARGININE VASOPRESSIN RESPONSE TO METOCLOPRAMIDE IN MAN , 1989, Clinical endocrinology.

[17]  P. Cowen,et al.  Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. , 1990, European journal of pharmacology.

[18]  F. Mitchelson Pharmacological agents affecting emesis. A review (Part I). , 1992, Drugs.

[19]  R. Dahl,et al.  Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. , 1992, Archives of general psychiatry.

[20]  X. Bertagna,et al.  Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin , 1993, Clinical endocrinology.

[21]  F A Mussa-Ivaldi,et al.  Adaptive representation of dynamics during learning of a motor task , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  L. Kar,et al.  Serotonergic regulation of renin and prolactin secretion , 1995, Behavioural Brain Research.

[23]  T. Dinan,et al.  Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. , 1996, Life sciences.

[24]  H. Westenberg,et al.  Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder , 1996, European Neuropsychopharmacology.

[25]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[26]  F. Cavagnini,et al.  Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[27]  S. Sekiya,et al.  Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea , 1997, Clinical endocrinology.

[28]  F. Mussa-Ivaldi,et al.  The motor system does not learn the dynamics of the arm by rote memorization of past experience. , 1997, Journal of neurophysiology.

[29]  T. Dinan,et al.  Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. , 1998, Life sciences.

[30]  P. Cowen,et al.  Brain 5-HT neurotransmission during paroxetine treatment , 1998, British Journal of Psychiatry.

[31]  M. Ferrari,et al.  Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. , 1998, Journal of clinical psychopharmacology.

[32]  Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  T. Dinan,et al.  Desmopressin augments pituitary–adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers , 1999, Biological Psychiatry.

[34]  G. Aguilera,et al.  Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation , 2000, Regulatory Peptides.

[35]  T. Endo,et al.  Neurochemistry and neuropharmacology of emesis - the role of serotonin. , 2000, Toxicology.

[36]  N. Danbolt Glutamate uptake , 2001, Progress in Neurobiology.

[37]  Carmine M Pariante,et al.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment , 2001, Biological Psychiatry.

[38]  A. Kjaer,et al.  Serotonergic Stimulation of Corticotropin‐Releasing Hormone and Pro‐Opiomelanocortin Gene Expression , 2002, Journal of neuroendocrinology.

[39]  R. Elliott,et al.  5-HT2C receptor activation by m-chlorophenylpiperazine detected in humans with fMRI , 2002, Neuroreport.

[40]  J. V. van Gerven,et al.  Placebo-Controlled Comparison of Three Dose-Regimens of 5-Hydroxytryptophan Challenge Test in Healthy Volunteers , 2002, Journal of clinical psychopharmacology.

[41]  N. Nicolson,et al.  L-5-Hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers , 2002, Psychopharmacology.

[42]  K. Schruers,et al.  Acute l-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients , 2002, Psychiatry Research.

[43]  T. Dinan,et al.  Vasopressin as a target for antidepressant development: an assessment of the available evidence. , 2002, Journal of affective disorders.